�°������ϲ���Ļ��Ϣ

Early detection of tumors is extremely important in treating cancer. A new technique developed by researchers at the University of California, Davis, offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from normal tissue. The work is published May 25 in the journal .

Chemical probes that produce a signal on magnetic resonance imaging, or MRI, can be used to target and image tumors. The new research is based on a phenomenon called magnetic resonance tuning that occurs between two nanoscale magnetic elements. One acts to enhance the signal, and the other quenches it. Previous studies have shown that quenching depends on the distance between the magnetic elements. This opens new possibilities for noninvasive and sensitive investigation of a variety of biological processes by MRI.

The �°������ϲ���Ļ��Ϣ Davis team created a probe that generates two magnetic resonance signals that suppress each other until they reach the target, at which point they both increase contrast between the tumor and surrounding tissue. They call this two-way magnetic resonance tuning, or TMRET.

Combined with specially developed imaging analysis software, the double signal enabled researchers to pick out brain tumors in a mouse model with greatly increased sensitivity.

“It’s a significant advance,” said senior author Yuanpei Li, associate professor of biochemistry and molecular medicine at the �°������ϲ���Ļ��Ϣ Davis School of Medicine and Comprehensive Cancer Center. “This could help detect very small early-stage tumors.”

Two magnetic components

The probe developed by the �°������ϲ���Ļ��Ϣ Davis team contains two components: nanoparticles of superparamagnetic iron oxide, or SPIO, and pheophorbide a–paramagnetic manganese, or P-Mn, packaged together in a lipid envelope. SPIO and P-Mn both give strong, separate signals on MRI, but as long as they are physically close together those signals tend to cancel each other out, or quench. When the particles enter tumor tissue, the fatty envelope breaks down, SPIO and P-Mn separate, and both signals appear.

Li’s laboratory focuses on the chemistry of MRI probes and developed a method to process the data and reconstruct images, which they call double-contrast enhanced subtraction imaging, or DESI. But for expertise in the physical mechanisms, they reached out to professors Kai Liu and Nicholas Curro at the �°������ϲ���Ļ��Ϣ Davis Department of Physics (Liu is now at Georgetown University). The physicists helped elucidate the mechanism of the TMRET method and refine the technique.

The researchers tested the method in cultures of brain and prostate cancer cells and in mice. For most MRI probes, the signal from the tumor is up to twice as strong as from normal tissue – a “tumor to normal ratio” of 2 or less. Using the new dual-contrast nanoprobe, Li and colleagues could get a tumor-to-normal ratio as high as 10.

Li said the team is interested in translating the research into clinical use, although that will require extensive work including toxicology testing and scaling up production before they could apply for investigational new drug approval.

Additional authors on the paper are: Xiangdong Xue, Hongwei Lu, Yixuan He, Ye Yuan, Courtney Dreyer, Kit Lam, Jeffrey Walton and Tzu-yin Lin, �°������ϲ���Ļ��Ϣ Davis School of Medicine; Angelique Louie, �°������ϲ���Ļ��Ϣ Davis Department of Biomedical Engineering; Zhijie Chen, �°������ϲ���Ļ��Ϣ Davis Department of Physics and Georgetown University; Zhongling Wang and Na Tang, Shanghai Jiaotong University; Ziwei Lu, First Affiliated Hospital of Soochow University, Suzhou, China; Lizabeth Quigley and Dustin Gilbert, University of Tennessee, Knoxville; and Katherine Ferrara, Stanford University.

The work was partly supported by grants from the National Institutes of Health and National Science Foundation.